Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies
“We are encouraged about the opportunity to establish a strategic scientific alliance with SCRI as we work together on initiatives aimed to address high unmet needs for patients battling cancer,” said Svetlana Kobina, MD., PhD., Vice President of AbbVie Oncology, Global Medical Affairs. “Through close collaboration with SCRI and its community sites, we hope to gain a more comprehensive understanding of the treatment paths and health needs of patients living with cancer to provide tailored, patient-centered scientific solutions. This partnership enables us to delve deeper into the challenges faced by medical oncologists, hematologists, patients and caregivers to help us design clinical studies that more accurately represent all patient communities.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a